Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKAN NASDAQ:CERO NYSE:NKGN NASDAQ:PLRZ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKANAkanda$3.33-7.1%$3.88$2.91▼$8.75$1.53M1.6152,374 shs13,363 shsCEROCERo Therapeutics$5.49+1.7%$7.71$4.27▼$895.40$6.64M0.47474,417 shs31,906 shsNKGNNKGen Biotech$0.13-7.0%$0.18$0.10▼$0.96$5.96M1.191.48 million shs21,440 shsPLRZPolyrizon$1.17-2.4%$1.08$0.55▼$1,200.00$7.01MN/A3.16 million shs1.76 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKANAkanda0.00%+3.77%-15.76%-10.50%-51.87%CEROCERo Therapeutics0.00%-8.78%-32.50%-21.40%-97.10%NKGNNKGen Biotech0.00%-7.02%-5.36%-56.69%-82.87%PLRZPolyrizon0.00%+17.65%+9.09%+49.59%+119,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKANAkanda$3.33-7.1%$3.88$2.91▼$8.75$1.53M1.6152,374 shs13,363 shsCEROCERo Therapeutics$5.49+1.7%$7.71$4.27▼$895.40$6.64M0.47474,417 shs31,906 shsNKGNNKGen Biotech$0.13-7.0%$0.18$0.10▼$0.96$5.96M1.191.48 million shs21,440 shsPLRZPolyrizon$1.17-2.4%$1.08$0.55▼$1,200.00$7.01MN/A3.16 million shs1.76 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKANAkanda0.00%+3.77%-15.76%-10.50%-51.87%CEROCERo Therapeutics0.00%-8.78%-32.50%-21.40%-97.10%NKGNNKGen Biotech0.00%-7.02%-5.36%-56.69%-82.87%PLRZPolyrizon0.00%+17.65%+9.09%+49.59%+119,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKANAkanda 0.00N/AN/AN/ACEROCERo Therapeutics 3.33Buy$45.00719.67% UpsideNKGNNKGen Biotech 0.00N/AN/AN/APLRZPolyrizon 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest AKAN, PLRZ, NKGN, and CERO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/5/2025CEROCERo TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$30.008/4/2025CEROCERo TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$30.006/23/2025CEROCERo TherapeuticsD Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy6/23/2025CEROCERo TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$30.00(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKANAkanda$840K1.82N/AN/A$9.37 per share0.35CEROCERo TherapeuticsN/AN/AN/AN/A($41.98) per shareN/ANKGNNKGen BiotechN/AN/AN/AN/A($2.68) per shareN/APLRZPolyrizonN/AN/AN/AN/A$315.05 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKANAkanda-$4.10MN/A0.00∞N/AN/AN/AN/AN/ACEROCERo Therapeutics-$8.30MN/A0.00∞N/AN/AN/A-209.40%N/ANKGNNKGen Biotech-$82.94M-$2.45N/A∞N/AN/AN/A-479.36%N/APLRZPolyrizon-$1.54MN/A0.00∞N/AN/AN/AN/AN/ALatest AKAN, PLRZ, NKGN, and CERO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/22/2025Q2 2025CEROCERo Therapeutics-$70.2290-$61.71+$8.5190-$61.71N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKANAkandaN/AN/AN/AN/AN/ACEROCERo TherapeuticsN/AN/AN/AN/AN/ANKGNNKGen BiotechN/AN/AN/AN/AN/APLRZPolyrizonN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKANAkandaN/A1.391.39CEROCERo TherapeuticsN/A0.560.56NKGNNKGen BiotechN/A0.020.02PLRZPolyrizonN/A10.1610.16Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKANAkanda1.00%CEROCERo Therapeutics29.64%NKGNNKGen Biotech76.17%PLRZPolyrizonN/AInsider OwnershipCompanyInsider OwnershipAKANAkanda20.39%CEROCERo Therapeutics12.72%NKGNNKGen Biotech10.36%PLRZPolyrizonN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKANAkanda110460,000364,000Not OptionableCEROCERo Therapeutics81.21 million1.05 millionN/ANKGNNKGen BiotechN/A44.95 million40.29 millionNot OptionablePLRZPolyrizonN/A5.99 millionN/AN/AAKAN, PLRZ, NKGN, and CERO HeadlinesRecent News About These CompaniesPolyrizon reports intranasal delivery of PL-14 Allergy Blocker in studySeptember 12 at 11:18 AM | msn.comPolyrizon Ltd. Announces Positive Preclinical Results for PL-14 Allergy Blocker as Potential Treatment for Allergic RhinitisSeptember 12 at 7:30 AM | quiverquant.comQPolyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest StudySeptember 12 at 7:26 AM | globenewswire.comPolyrizon (NASDAQ:PLRZ) versus ALX Oncology (NASDAQ:ALXO) Head-To-Head ContrastSeptember 5, 2025 | americanbankingnews.comPolyrizon Regains Nasdaq ComplianceAugust 14, 2025 | msn.comPolyrizon Ltd. Regains Compliance with Nasdaq Listing RequirementsAugust 14, 2025 | quiverquant.comQPolyrizon Regains Compliance with Nasdaq Listing RequirementsAugust 14, 2025 | globenewswire.comPolyrizon Ltd. Announces Special General Meeting for September 2025July 31, 2025 | tipranks.comPolyrizon stock soars after promising nasal allergy blocker test resultsJuly 23, 2025 | in.investing.comPolyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest StudyJuly 22, 2025 | globenewswire.comPolyrizon Ltd.: Polyrizon Retains Nasdaq Listing Following Hearings PanelJuly 15, 2025 | finanznachrichten.dePolyrizon retains Nasdaq listing following hearings panelJuly 15, 2025 | msn.comPolyrizon Retains Nasdaq Listing Following Hearings PanelJuly 15, 2025 | globenewswire.comPolyrizon’s nasal drug delivery system shows promising resultsJune 14, 2025 | uk.investing.comPolyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its ...June 12, 2025 | bakersfield.comBPolyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its Innovative Hydrogel Formulation for CNS TherapeuticsJune 12, 2025 | globenewswire.comPolyrizon Ltd. Receives Nasdaq Notification of Potential Delisting Due to Shareholder Dilution ConcernsMay 23, 2025 | quiverquant.comQPolyrizon Announces Receipt of Nasdaq Delisting NoticeMay 23, 2025 | globenewswire.comPolyrizon Ltd. Announces Reverse Share Split Effective May 27, 2025May 22, 2025 | tipranks.comPolyrizon Emerges with Positive Preclinical Data on Nasal Protection PlatformMay 21, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAKAN, PLRZ, NKGN, and CERO Company DescriptionsAkanda NASDAQ:AKAN$3.32 -0.26 (-7.12%) As of 02:55 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Akanda Corp., through its subsidiaries, engages in the cultivation, manufacture, and distribution of cannabis products to patients worldwide. It offers medicinal-grade cannabis and cannabis based medical and wellness products. The company was incorporated in 2021 and is headquartered in New Romney, the United Kingdom.CERo Therapeutics NASDAQ:CERO$5.49 +0.09 (+1.67%) As of 03:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.NKGen Biotech NYSE:NKGN$0.13 -0.01 (-7.02%) As of 02:07 PM EasternNKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.Polyrizon NASDAQ:PLRZ$1.17 -0.03 (-2.44%) As of 02:45 PM EasternPolyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Royal Caribbean's 33% Dividend Hike Signals Deeper Growth MarketBeat Week in Review – 09/08 - 09/12 Adobe’s Rebound Has Room to Run: 25% Upside by Year-End Wall Street Eyes +30% Upside in Synopsys After Huge Earnings Fall Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
